Lyme Disease and Post-treatment Lyme Disease Syndrome: Current and Developing Treatment Options

Lyme disease and its treatment implications have become an ever-increasing area of concern within the United States related to the markedly increased prevalence of infection within the last two decades. The presentation, pathophysiology, and epidemiology of Lyme disease have been well studied, and thus treatments for this disease are widely available. While the treatment of its early and late stages is relatively simple with 10-14 day and four-week courses of doxycycline, respectively, the main problem rests in the understanding of the etiology and pathology of post-treatment Lyme disease syndrome (PTLDS). With the time of symptoms onsetting approximately six months after treatment and potentially lasting indefinitely, this syndrome's effect on patients' quality of life could be devastating. Searching on PubMed, Google Scholar, MEDLINE, and ScienceDirect using keywords including Lyme disease, PTLDS, doxycycline, erythema migrans, azlocillin, and treatment, the authors have tried to make clear the different aspects. The authors have reviewed and discussed clinical studies of Lyme disease and its treatments/potential therapeutics as well as PTLDS and its sparse treatments/potential therapeutics.

[1]  A. Kaye,et al.  Tetracycline-, Doxycycline-, Minocycline-Induced Pseudotumor Cerebri and Esophageal Perforation , 2023, Advances in Therapy.

[2]  S. Zimmerli,et al.  [Lyme Disease - Epidemiology and Pathophysiology]. , 2022, Therapeutische Umschau. Revue therapeutique.

[3]  P. Mead.  Epidemiology of Lyme Disease. , 2022, Infectious disease clinics of North America.

[4]  B. Fallon,et al.  Kundalini Yoga for Post-Treatment Lyme Disease: A Preliminary Randomized Study , 2022, Healthcare.

[5]  Alison W. Rebman,et al.  Risk of post-treatment Lyme disease in patients with ideally-treated early Lyme disease: A prospective cohort study. , 2022, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[6]  B. Biggerstaff,et al.  Evaluating public acceptability of a potential Lyme disease vaccine using a population-based, cross-sectional survey in high incidence areas of the United States. , 2021, Vaccine.

[7]  E. Shapiro,et al.  A Review of Post-treatment Lyme Disease Syndrome and Chronic Lyme Disease for the Practicing Immunologist , 2021, Clinical Reviews in Allergy & Immunology.

[8]  V. Soti,et al.  Post-Treatment Lyme Disease Syndrome: Need for Diagnosis and Treatment , 2021, Cureus.

[9]  A. Hinckley,et al.  Effects of COVID-19 Pandemic on Reported Lyme Disease, United States, 2020 , 2021, Emerging infectious diseases.

[10]  Y. Yehudina,et al.  Lyme Borreliosis as a Trigger for Autoimmune Disease , 2021, Cureus.

[11]  D. Klepacki,et al.  A selective antibiotic for Lyme disease , 2021, Cell.

[12]  F. Strle,et al.  Comparison of Lyme Disease in the United States and Europe , 2021, Emerging infectious diseases.

[13]  L. Joosten,et al.  Prevalence of persistent symptoms after treatment for lyme borreliosis: A prospective observational cohort study , 2021, The Lancet regional health. Europe.

[14]  G. Wormser,et al.  Aggregation of data from 4 clinical studies demonstrating efficacy of single-dose doxycycline postexposure for prevention of the spirochetal infections: Lyme disease, syphilis, and tick-borne relapsing fever. , 2020, Diagnostic microbiology and infectious disease.

[15]  Alison W. Rebman,et al.  A Distinct Microbiome Signature in Posttreatment Lyme Disease Patients , 2020, mBio.

[16]  C. C. van den Wijngaard,et al.  A single dose of doxycycline after an Ixodes ricinus tick bite to prevent Lyme borreliosis: an open-label randomized controlled trial. , 2020, The Journal of infection.

[17]  B. Kullberg,et al.  Lyme borreliosis: diagnosis and management , 2020, BMJ.

[18]  G. Nabel,et al.  Design of a broadly reactive Lyme disease vaccine , 2020, npj Vaccines.

[19]  V. Mallajosyula,et al.  Azlocillin can be the potential drug candidate against drug-tolerant Borrelia burgdorferi sensu stricto JLB31 , 2020, Scientific Reports.

[20]  Post-Treatment Lyme Disease Syndrome , 2020, Definitions.

[21]  R. Schoen.  Challenges in the Diagnosis and Treatment of Lyme Disease , 2020, Current Rheumatology Reports.

[22]  E. Fikrig,et al.  Protective Immunity and New Vaccines for Lyme Disease , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  A. Delong,et al.  Estimation of cumulative number of post-treatment Lyme disease cases in the US, 2016 and 2020 , 2019, BMC Public Health.

[24]  C. Brayton,et al.  Stationary phase persister/biofilm microcolony of Borrelia burgdorferi causes more severe disease in a mouse model of Lyme arthritis: implications for understanding persistence, Post-treatment Lyme Disease Syndrome (PTLDS), and treatment failure. , 2019, Discovery medicine.

[25]  J. A. Cárdenas-de la Garza,et al.  Clinical spectrum of Lyme disease , 2018, European Journal of Clinical Microbiology & Infectious Diseases.

[26]  K. Fairman,et al.  Adverse Events Associated With Antibiotics and Intravenous Therapies for Post–Lyme Disease Syndrome in a Commercially Insured Sample , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  Alison W. Rebman,et al.  The Clinical, Symptom, and Quality-of-Life Characterization of a Well-Defined Group of Patients with Posttreatment Lyme Disease Syndrome , 2017, Front. Med..

[28]  C. Ski,et al.  Yoga, mindfulness-based stress reduction and stress-related physiological measures: A meta-analysis , 2017, Psychoneuroendocrinology.

[29]  A. Meinke,et al.  The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes , 2017, PloS one.

[30]  P. Mead,et al.  Serious Bacterial Infections Acquired During Treatment of Patients Given a Diagnosis of Chronic Lyme Disease — United States , 2017, MMWR. Morbidity and mortality weekly report.

[31]  R. Marconi,et al.  Identification of a defined linear epitope in the OspA protein of the Lyme disease spirochetes that elicits bactericidal antibody responses: Implications for vaccine development , 2017, Vaccine.

[32]  W. van Biesen,et al.  Ceftriaxone-induced immune hemolytic anemia as a life-threatening complication of antibiotic treatment of ‘chronic Lyme disease’ , 2017, Acta clinica Belgica.

[33]  Joyce L. Sanchez.  Clinical Manifestations and Treatment of Lyme Disease. , 2015, Clinics in laboratory medicine.

[34]  P. Mead,et al.  Geographic Distribution and Expansion of Human Lyme Disease, United States , 2015, Emerging infectious diseases.

[35]  B. Chomel.  Lyme disease: -EN- -FR- La maladie de Lyme -ES- Enfermedad de Lyme , 2015 .

[36]  K. Lewis,et al.  Borrelia burgdorferi, the Causative Agent of Lyme Disease, Forms Drug-Tolerant Persister Cells , 2015, Antimicrobial Agents and Chemotherapy.

[37]  Jie Feng,et al.  Drug Combinations against Borrelia burgdorferi Persisters In Vitro: Eradication Achieved by Using Daptomycin, Cefoperazone and Doxycycline , 2015, PloS one.

[38]  M. Hanner,et al.  Design and Development of a Novel Vaccine for Protection against Lyme Borreliosis , 2014, PloS one.

[39]  L. Bockenstedt,et al.  Xenodiagnosis for posttreatment Lyme disease syndrome: resolving the conundrum or adding to it? , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  F. Strle,et al.  Lyme borreliosis , 2012, The Lancet.

[41]  Gregory A Poland,et al.  Vaccines against Lyme disease: What happened and what lessons can we learn? , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  J. Parsonnet,et al.  Final report of the Lyme disease review panel of the Infectious Diseases Society of America. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  Michelle A. Mathiason,et al.  Antibiotic treatment duration and long-term outcomes of patients with early lyme disease from a lyme disease-hyperendemic area. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  S. Barthold,et al.  Persistence of Borrelia burgdorferi following Antibiotic Treatment in Mice , 2008, Antimicrobial Agents and Chemotherapy.

[45]  E. Fikrig,et al.  Salivating for Knowledge: Potential Pharmacological Agents in Tick Saliva , 2008, PLoS medicine.

[46]  W. Heiss,et al.  Mild Cognitive Impairment – MCI , 2007 .

[47]  K. Thompson,et al.  The Lyme vaccine: a cautionary tale , 2006, Epidemiology and Infection.

[48]  S. Eppes,et al.  Comparative study of cefuroxime axetil versus amoxicillin in children with early Lyme disease. , 2002, Pediatrics.

[49]  D. Dennis,et al.  Surveillance for Lyme disease--United States, 1992-1998. , 2000, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[50]  M. Gerber.  Lyme disease vaccine. , 1999, Health news.

[51]  A. Mccarthy.  Development , 1996, Current Opinion in Neurobiology.

[52]  R. Nadelman,et al.  Comparison of Cefuroxime Axetil and Doxycycline in the Treatment of Early Lyme Disease , 1992, Annals of Internal Medicine.

[53]  Jean Côté,et al.  Lyme Disease , 1991, International journal of dermatology.

[54]  A. Steere,et al.  Lyme borreliosis , 2016, Nature Reviews Disease Primers.